Silexion Therapeutics Reports Q3 2024 Results, Advances Cancer Treatment Pipeline
TL;DR
Silexion completed a strategic business combination, gaining access to greater capital for advancing clinical pipeline.
Silexion's first-generation candidate, LODER, demonstrated a 56% objective response rate in Phase 2 trial for non-resectable pancreatic cancer.
Silexion's advancements in RNAi therapies have the potential to improve surgical outcomes and overall survival for patients with challenging pancreatic cancer.
Silexion's next-generation candidate, SIL-204, demonstrated substantial anti-tumor effects and enhanced stability in preclinical studies.
Found this article helpful?
Share it with your network and spread the knowledge!
Silexion Therapeutics (NASDAQ: SLXN) has reported its third quarter 2024 financial results and provided updates on its clinical programs for KRAS-driven cancers. The company, which recently went public through a merger with Moringa Acquisition Corp, is advancing its pipeline of RNA interference (RNAi) therapies targeting difficult-to-treat solid tumors.
Silexion's lead candidate, LODER, showed a 56% objective response rate in a Phase 2 trial for non-resectable pancreatic cancer patients with specific KRAS mutations. The treatment improved tumor resectability to 67% in some cases, highlighting its potential to enhance surgical outcomes and survival rates for patients with locally advanced pancreatic cancer.
The company is also making strides with its next-generation candidate, SIL-204. Preclinical studies demonstrated significant anti-tumor effects and improved stability, with plans to initiate Phase 2/3 clinical trials by early 2026. Silexion is expanding its research to include colorectal cancer applications for SIL-204, broadening its potential impact across multiple KRAS-driven cancers.
Financially, Silexion reported $2.0 million in cash and cash equivalents as of September 30, 2024, down from $4.6 million at the end of 2023. The company's net loss for Q3 2024 increased to $11.9 million, compared to $0.8 million in the same period last year, primarily due to increased research and development expenses, administrative costs associated with becoming a public company, and non-cash items related to share-based compensation.
The transition to a public company and advancement of its clinical pipeline mark significant milestones for Silexion. As the company progresses its innovative RNAi therapies, it aims to address the unmet needs in KRAS-mutated cancers, potentially offering new treatment options for patients with limited alternatives. The coming years will be crucial as Silexion moves its candidates through clinical trials and seeks to validate its approach in larger patient populations.
Curated from News Direct
